Effects of Yiqi Fumai injection combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure
Objective:To observe effects of Yiqi Fumai injection combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure. Methods:The clinical data of 114 patients with chronic heart failure admitted to this hospital from April 2022 to June 2023 were retrospectively analyzed. According to different treatment methods,they were divided into control group and study group,57 cases in each group. The control group was treated with Sacubitril/Valsartan,while the study group was treated with Yiqi Fumai injection on the basis of that of the control group. The clinical efficacy,the severity of symptoms[Memorial symptom assessment scale-heart failure (MSAS-HF)]score and the serum biochemical indexes[N-terminal pro-brain natriuretic peptide (NT-proBNP),cardiac troponin T (cTnT),creatine kinase isoenzyme (CK-MB)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of the study group was 92.98％ (53/57),which was higher than 78.95％ (45/57) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the MSAS-HF scores of physiological symptoms,psychological symptoms and heart failure in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). After the treatment,the levels of serum NT-proBNP,cTnT and CK-MB in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Yiqi Fumai injection combined with Sacubitril/Valsartan in the treatment of the patients with chronic heart failure can improve the total effective rate of treatment and reduce the MSAS-HF scores and the serum biochemical index levels. Moreover,it is superior to simple Sacubitril/Valsartan treatment.
万方数据
维普
